Biotech and life sciences investors outside Boston and the Bay Area

• 1,373 of 4,302 US biotech investor records are outside CA, NY and MA.
• Texas (143) and Washington (130) lead outside the big three.
• Pre-seed is thin: 32.7% of biotech records with a stage.
• Regional biotech rounds stack grants, physician angels and regional funds.
• Hub specialists usually arrive at Series A, once data is in hand.

Boston and the Bay Area are the centers of gravity for biotech venture capital, and our data reflects it: Massachusetts and California together hold more than half of the US biotech and life sciences investor records in the Zalarma database. But that still leaves a meaningful pool elsewhere. 1,373 of the 4,302 US records with a biotech focus have a known state outside California, New York and Massachusetts (Zalarma investor database, as of 2026-11-01). For a founder spinning out of a university in Texas, North Carolina, Maryland or Missouri, that pool is where an opening round usually comes from.

The national picture

Of the 4,302 biotech records, 1,396 list pre-seed, 3,880 list seed and 2,702 list Series A. Biotech is the sector where pre-seed is thinnest relative to later stages: only 32.7% of biotech records with a stage list pre-seed, against 39.6% across all US records. Angels account for 1,114 records. Checks lean larger: 903 list $1M or more.

Biotech investors by state, outside the big three

Texas (143) and Washington (130) lead, followed by Florida, Illinois and Pennsylvania. Several smaller life sciences hubs show up clearly: North Carolina's Research Triangle (69 records), Maryland near the federal research institutions (53), Missouri around St. Louis (49) and Connecticut (51). By metro, Seattle (114), Chicago (103) and San Diego are the biggest pools outside Boston, New York and the Bay Area.

Firms with biotech investors outside the coasts

Firms with the most biotech-focused investors listed outside California, New York and Massachusetts include VentureSouth (25 listed), Alliance of Angels (17), Moving Capital (13) and ARCH Venture Partners (10), a major life sciences investor with roots in Chicago. Hatteras Venture Partners in North Carolina, Bios Partners in Texas, Baird Capital and Connecticut Innovations also appear, along with the Wolfpack Investor Network. Thompson Street Capital Partners appears often but invests at later stages.

How regional biotech rounds usually work

Biotech companies outside the hubs often follow a recognizable path:

1. University and non-dilutive funding. Tech transfer support, university gap funds, state programs and federal research grants fund early proof of concept.
2. Angels and angel groups with medical backgrounds. Physicians and former industry executives write early checks. Regional networks such as VentureSouth and Wolfpack Investor Network list biotech investors.
3. A regional life sciences fund. State-supported and university-linked funds often lead seed rounds.
4. Specialist funds from the hubs. Boston and Bay Area specialists usually arrive at Series A, once data is in hand.

What biotech investors want to see

• Data, not just a mechanism. Early efficacy data, even in a model system, changes the conversation.
• A clear development plan and budget to the next value-creating milestone.
• IP position. A clean license from the university and freedom to operate.
• The right team. Scientific founders plus experienced development and business leadership, even part time.

A hypothetical university spinout

Consider a hypothetical St. Louis spinout with a licensed diagnostic platform and early validation data from a university lab. A practical path: a state or federal research grant to fund the next validation study, $300K from physician angels and a regional angel network, then a $2M seed led by a Midwest life sciences fund once the study reads out. Boston specialists would enter at Series A with clinical data in hand. At each step, the company spends less than it would in a coastal hub and gives up less ownership before the data that drives valuation arrives.

A biotech raise outside the hubs

• Stack non-dilutive money early. Check each program's current rules on its official site.
• Find physician and industry angels locally. They are the most common pre-seed biotech investors outside the hubs.
• Use regional life sciences funds to lead seed. Then bring in hub specialists with data.
• Consider staying put. Lower costs and university ties can stretch a seed round much further than in Boston.

Explore the biotech investors page and our healthcare investors brief, or ask us to hand-pick five life sciences investors who fit your stage.

How we counted

Counts are records in the Zalarma investor database tagged as startup investors with a US location, as of 2026-11-01. A record is a person or a firm, and one record can list several stages, sectors and check sizes, so columns do not add up to the total. Shares use only records where that field is known. We never publish a count under 10; a dash means fewer than 10. Outside the big three means a record with a known US state other than California, New York or Massachusetts. Firm counts are shown only when 10 or more. More on sources in our data.